3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Unknown
1
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
25
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Leukemia
9
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma
8
Burkitt Lymphoma
6
Recurrence
5
Lymphoma, Follicular
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large-Cell, Anaplastic
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Leukemia, Biphenotypic, Acute
4
Sezary Syndrome
3
Myelodysplastic Syndromes
3
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Immunoblastic Lymphadenopathy
3
Hodgkin Disease
3
Blast Crisis
3
Waldenstrom Macroglobulinemia
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Extranodal NK-T-Cell
2
Lymphoma, B-Cell
2
Lymphoma, AIDS-Related
2
Leukemia, Myelomonocytic, Chronic
2
Interventions
pertuzumab
1
cc-486
1
Trastuzumab
1
Sulindac
1
Magnetic Resonance Spectroscopy
1
Epirubicin
1
Docetaxel
1
Cytarabine
1
Carboplatin
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Pathologic Complete Response
×
Cytarabine
×
Clear all
NCT01843179
2017-02-17
Sulindac for Patients With AML
Massachusetts General Hospital
Phase 2
Withdrawn